CC Small or few human trials. Promising, not proven. How we grade →Biomarker substudy of an RCT · REDUCE-IT participants
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
P Ridker, N Rifai, J MacFadyen, R Glynn, L Jiao, P Steg et al. Circulation. 2022.
- In plain language
- Atherosclerosis-linked markers rose in REDUCE-IT's mineral oil group (for example, hs-CRP up 21.9% at 12 months) and barely changed with icosapent ethyl; impact on the event results is uncertain.
- Limits
- Biomarkers, not events; cannot settle how much the placebo shaped REDUCE-IT's result.
- Which of our grades it feeds
- BB Good human data, but mixed outcomes or surrogate markers. How we grade →Science summary: Omega-3 dose and form: how much EPA and DHA, and does triglyceride vs ethyl ester matter?
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Omega-3: triglycerides, heart outcomes and why the big trials differ
- Source
- doi.org/10.1161/CIRCULATIONAHA.122.059410 · PubMed 35762321
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.